We are national leaders in advanced veterinary therapies
EquiCord was born in 2012 in the hands of a multidisciplinary team formed up of veterinarians, biologists, engineers and pharmacists.
After positioning ourselves as national leaders in advanced veterinary therapies, we decided to take the leap into the European pharmaceutical industry by conducting various safety / efficacy clinical trials and building pioneering GMP facilities in the veterinary biotechnology sector.
After years of research, in 2019 we received the first European license for a drug based on Equine Umbilical Cord Mesenchymal Stem Cells (EUC-MSCs): HorStem®
Following the success of HorStem®, in 2022 EquiCord received unanimous marketing authorisation for DogStem®: the world's first stem cell-based medicine for the treatment of canine osteoarthritis.